Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Eravacycline

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Everest Medicines Announces Commercial Launch and First Prescription for XERAVA
    Everest Medicines Announces Commercial Launch and First Prescription for XERAVA

    26 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/everest-medicines-announces-commercial-launch-and-first-prescription-for-xerava-in-china-301886863.html

    PR NEWSWIRE
    26 Jul 2023
    Share Share
    Everest Medicines Announces Approval of Xerava in China
    Everest Medicines Announces Approval of Xerava in China

    17 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/everest-medicines-announces-approval-of-xerava-in-china-for-the-treatment-of-complicated-intra-abdominal-infections-in-adult-patients-301774097.html

    PR NEWSWIRE
    17 Mar 2023
    Share Share
    La Jolla Announces Data on XERAVA to be Presented at IDWeek 2022
    La Jolla Announces Data on XERAVA to be Presented at IDWeek 2022

    14 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221014005417/en

    BUSINESSWIRE
    14 Oct 2022
    Share Share
    Everest Medicines Announces Approval of XERAVA in Hong Kong
    Everest Medicines Announces Approval of XERAVA in Hong Kong

    07 Oct 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/everest-medicines-announces-approval-of-xerava-in-hong-kong-for-the-treatment-of-complicated-intra-abdominal-infections-301643527.html

    PRNEWSWIRE
    07 Oct 2022
    Share Share
    Everest Medicines gets China NMPA approval to begin phase 3 trial of Xeravam
    Everest Medicines gets China NMPA approval to begin phase 3 trial of Xeravam

    06 Aug 2021

    // PHARMABIZ

    http://www.pharmabiz.com/ArticleDetails.aspx?aid=140617&sid=2

    PHARMABIZ
    06 Aug 2021
    Share Share
    La Jolla Company Announces Exclusive Licensing Agreement for GIAPREZA™
    La Jolla Company Announces Exclusive Licensing Agreement for GIAPREZA™

    12 Jan 2021

    // NASDAQ

    https://www.nasdaq.com/press-release/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for

    NASDAQ
    12 Jan 2021
    Share Share